Stemline Therapeutics (STML) is a biopharmaceutical company that is developing cancer therapies targeting cancer stem cells. Stemline presented some exciting results for its lead program SL-104 this weekend at the American Society of Clinical Oncology (OTC:ASCO) meeting in Chicago, validating the company as a strong contender in the cancer stem cell treatment space. The data for lead candidate SL-401 included a response for 5 out of 6 blastic plasmacyoid dendritic cell neoplasm (BPDCN) patients and an increase in overall survival for refractory/relapsed acute myeloid leukemia (AML) patients. SL-401 is a recombinant protein consisting of human interleukin-3 (IL-3), designed to find IL-3 receptors on cancer cells and cancer stem cells, bound to a toxic payload.
Only subscribers can access this article, which is part of the PRO research library covering 3,590 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: